SCOTUS Deals Teva Crucial Blow In Drawn-Out Copaxone Patent Battle

Generic Line
The Supreme Court Nov. 13 dealt generic giant Teva a major blow as it denied the company’s request to stay a lower court’s ruling that will allow generic versions of the drugmaker’s blockbuster brand drug Copaxone to hit pharmacy shelves in May.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00